{
  "id": "5c65897a7c78d69471000006",
  "type": "factoid",
  "question": "Which was the first mutant IDH2 inhibitor to be approved for patients with acute myeloid leukemia?",
  "ideal_answer": "Enasidenib was the first mutant IDH2 inhibitor to be approved for the treatment of refractory and relapsed acute myeloid leukemia.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/30360730"
  ],
  "snippets": [
    {
      "text": "Enasidenib: First Mutant IDH2 Inhibitor for the Treatment of Refractory and Relapsed Acute Myeloid Leukemia.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30360730",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "The various findings about enasidenib revealed that it has been designed to allosterically inhibit mutated IDH2 to treat R/R AML patients",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30360730",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Enasidenib or AG-221was introduced by FDA as an anticancer agent which was developed as a first in class, a selective allosteric inhibitor of the tumor target i.e. IDH2 for Relapsed or Refractory AML. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30360730",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "Enasidenib"
}